cro.directory
← Compare landing

Genevoyager (Wuhan) Co., Ltd. vs uBriGene

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/genevoyager-2/ubrigene

CategoryGenevoyager (Wuhan) Co., Ltd.uBriGene
Listed sitebothboth
SummaryLeading CRO/CDMO provider specializing in viral vectors, proteins, and vaccines with proprietary AAV manufacturing technology and cGMP-grade facilities operational since October 2023.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing. Headquartered in Maryland with operations across North America and Asia, the company specializes in bridging ATMP concepts from early…
Services
  • Translational Research
  • Analytical Method Development & Validation
  • Regulatory Affairs
  • Analytical Method Development & Validation
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Biologics (Other)
  • Vaccine
  • AAV / Viral Vector Platform
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
IndicationsData not yet provided.
  • Oncology
Locations
  • Headquarters & cGMP Facility, Wuhan, Jiangxia District, China
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • China · Identifier: High-tech Enterprise (高新技术企业)
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.